

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066778-0389	SERIAL NO. 10/549,482
	APPLICANT Daniel J. Carr et al.	
	FILING DATE September 16, 2005	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 5,564,332	10-15-1996	Hoogenboom et al.	
	2.	US 5,264,563		Huse	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code ³ -Number 4 -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	**3.	ATHERTON and STREILEIN, "Two waves of virus following anterior chamber inoculation of HSV-1," <u>Invest. Ophthalmol. Vis. Sci.</u> 28:571-579 (1987).	
	**4.	AZUMI and ATHERTON, "Sparing of the ipsilateral retina after anterior chamber inoculation of HSV-1: requirement for either CD4+ or CD8+ T cells," <u>Invest. Ophthalmol. Vis. Sci.</u> 35:3251-3259 (1994).	
	**5.	BASS, "RNA interference. The short answer," <u>Nature</u> 411:428-429 (2001).	
	**6.	BORRABECK, <i>Antibody Engineering</i> , 2d ed., Oxford University Press (1995).	
	**7.	BOULEY et al., "Characterization of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-gamma knockout mice," <u>J. Immunol.</u> 155:3964-3971 (1995).	
	**8.	BRISSETTE-STORKUS et al., "Identification of a novel macrophage population in the normal mouse corneal stroma," <u>Invest. Ophthalmol. Vis. Sci.</u> 43:2264-2271 (2002).	
	**9.	BUSTOS and ATHERTON, "Detection of herpes simplex virus type 1 in human ciliary ganglia," <u>Invest. Ophthalmol. Vis. Sci.</u> 43:2244-2249 (2002).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066778-0389	SERIAL NO. 10/549,482
	APPLICANT Daniel J. Carr et al.	
	FILING DATE September 16, 2005	GROUP 1644

**10.	CANTIN et al., "Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1," <u>J. Virol.</u> 69:4898-4905 (1995).	
**11.	CARR and NOISAKRAN, "The antiviral efficacy of the murine alpha-1 interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4(+), alpha/beta T-cell receptor-positive T lymphocytes with the capacity to produce gamma interferon," <u>J. Virol.</u> 76:9398-9406 (2002).	
**12.	CARR et al., "The Immune Response to Ocular Herpes Simplex Virus Type 1 Infection," <u>Exp. Biol. Med.</u> 226:353-366 (2001).	
**13.	CARR et al., "Unforeseen consequences of IL-12 expression in the eye of GFAP-IL12 transgenic mice following herpes simplex virus type 1 infection," <u>DNA and Cell Biology</u> 21:467-473 (2002).	
**14.	CELLA et al., "Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon," <u>Nat. Med.</u> 5:919-923 (1999).	
**15.	CHEN and HENDRICKS, "B7 costimulatory requirements of T cells at an inflammatory site," <u>J. Immunol.</u> 160:5045-5052 (1998).	
**16.	LARKIN, et al., "Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection," <u>Clin Exp Immunol.</u> 107:381 (1997).	
**17.	COLE et al., "Different strains of Pseudomonas aeruginosa isolated from ocular infections or inflammation display distinct corneal pathologies in an animal model," <u>Curr. Eye. Res.</u> 17(7):730-735 (1998).	
**18.	COWARD et al., "Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors," <u>Anal. Biochem.</u> 270:242-248 (1999).	
**19.	DAHESHIA et al., "Production of key molecules by ocular neutrophils early after herpetic infection of the cornea," <u>Exp. Eye Res.</u> 67:619-624 (1998).	
**20.	DANA, "ENHANCING CORNEAL GRAFT SURVIVAL: Exploiting the Cytokine System," <u>Research to Prevent Blindness (RPB)</u> , 1-5. http://www.rpbusa.org	
**21.	DENNIS et al., "Involvement of LFA-1 and ICAM-1 in the herpetic disease resulting from HSV-1 corneal infection," <u>Current Eye Res.</u> 14:55-62 (1995).	
**22.	DIAB et al., "Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis," <u>Infect. Immun.</u> 67:2590-2601 (1999).	
**23.	EICHLER et al., "Peptide, peptidomimetic, and organic synthetic combinatorial libraries," <u>Med. Res. Rev.</u> 15:481-496 (1995).	
**24.	ELBASHIR et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <u>Nature</u> 411:494-498 (2001).	
**25.	ELLIS and BEAMAN, Murine polymorphonuclear neutrophils produce interferon-gamma in response to pulmonary infection with Nocardia asteroides," <u>J. Leukoc. Biol.</u> 72:373-381 (2002).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066778-0389	SERIAL NO. 10/549,482
	APPLICANT Daniel J. Carr et al.	
	FILING DATE September 16, 2005	GROUP 1644

**26.	ENGLER et al., "Experimental infection of inbred mice with herpes simplex virus. II. Interferon production and activation of natural killer cells in the peritoneal exudate," <u>J. Gen. Virol.</u> 55:25-30 (1981).	
**27.	FENTON et al., "Experimental infection of inbred mice with herpes simplex virus. II. Interferon production and activation of natural killer cells in the peritoneal exudate," <u>Invest. Ophthalmol. Vis. Sci.</u> 43:737-743 (2001).	
**28.	FIORENTINI et al., "Humanization of an antibody recognizing a breast cancer specific epitope by CDR-grafting," <u>Immunotechnology</u> 3(1):45-59 (1997).	
**29.	FRANCIS et al., "Combinatorial libraries of transition-metal complexes, catalysts and materials," <u>Curr. Opin. Chem. Biol.</u> 2:422-428 (1998).	
**30.	GONZALEZ et al., "Intracellular detection assays for high-throughput screening," <u>Curr. Opin. In Biotech.</u> 9:624-631 (1998).	
**31.	HARLE et al., "Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication," <u>J. Virol.</u> 76:6558-6567 (2002).	
**32.	HARLOW and LANE, <u>Antibodies: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988).	
**33.	HAUGLAND, <u>Molecular Probes -- Handbook of Fluorescent Probes and Research Chemicals</u> , Sets 20-23 and 25, Invitrogen Corporation, Carlsbad, CA (1992-94).	
**34.	HENDRICKS et al., "Critical role of corneal Langerhans cells in the CD4- but not CD8-mediated immunopathology in herpes simplex virus-1-infected mouse corneas," <u>J. Immunol.</u> 148:2522 (1992).	
**35.	HENDRICKS et al., "IFN-gamma and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice," <u>J. Immunol.</u> 149:3023-3028 (1992).	
**36.	HERBORT, et al., "Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection," <u>Jpn. J. Ophthalmol.</u> 33(2):212-220 (1989).	
**37.	HERMANSON, <u>Bioconjugate Techniques</u> , Academic Press, Burlington, MA (1996).	
**38.	HILL and MASKE, "Stimulation of cell replication in transplanted pancreatic islets by nicotinamide treatment," <u>Transplantation</u> 46:26-30 (1998).	
**39.	HILYARD et al, <u>Protein Engineering: A Practical Approach</u> , IRL Press, Oxford, England (1992).	
**40.	HUME et al., "Serratia marcescens keratitis: strain-specific corneal pathogenesis in rabbits," <u>Curr. Eye Res.</u> 19(6):525-532 (1999).	
**41.	HUNTER, et al., "Corneal graft rejection: a new rabbit model and cyclosporin-A," <u>Br. J. Ophthalmol.</u> 66(5):292-302 (1982).	
**42.	HUSE et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," <u>Science</u> 246:1275-1281 (1989).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066778-0389	SERIAL NO. 10/549,482
	APPLICANT Daniel J. Carr et al.	
	FILING DATE September 16, 2005	GROUP 1644

**43.	IGIETSEME et al., "Mechanisms of protection against herpes simplex virus type 1-induced retinal necrosis by in vitro-activated T lymphocytes," <u>J. Virol.</u> 65:763 (1991).	
**44.	JAYASENA, "Aptamers: an emerging class of molecules that rival antibodies in diagnostics," <u>Clinical Chemistry</u> 45(9):1628-1650 (1999).	
**45.	JAYAWICKREME et al., "Gene expression systems in the development of high-throughput screens," <u>Curr. Opin. Biotech.</u> 8:629-634 (1997).	
**46.	JINQUAN et al., "CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma," <u>Blood</u> 96:1230-1238 (2000).	
**47.	JINQUAN et al., "CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma," <u>J. Immunol.</u> 165:1548-1556 (2000).	
**48.	KARABINOS et al., "Essential roles for four cytoplasmic intermediate filament proteins in Caenorhabditis elegans development," <u>Proc. Natl. Acad. Sci. USA</u> 98:7863-7868 (2001).	
**49.	KUMARAGURU et al., "Chemokines and ocular pathology caused by corneal infection with herpes simplex virus," <u>J. Leukoc. Biol.</u> 71:469-476 (2002).	
**50.	LAU, et al., "A murine model of interlamellar corneal transplantation," <u>Br. J. Ophthalmol.</u> , 82(3):294-299 (1998).	
**51.	LEE et al., "IL-12 suppresses the expression of ocular immunoinflammatory lesions by effects on angiogenesis," <u>J. Leukoc. Biol.</u> , 71:469-476 (2002).	
**52.	LIU et al., "Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis," <u>J. Immunol.</u> 167:4091 (2001).	
**53.	LOETSCHER et al., "Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes," <u>J. Exp. Med.</u> 184:963-969 (1996).	
**54.	MAHALINGAM et al., "The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo," <u>J. Virol.</u> 73:1479 (1999).	
**55.	MAJOR, "Challenges of high throughput screening against cell surface receptors," <u>J. Receptor and Signal Transduction Res.</u> 15:595-607 (1995).	
**56.	MCLEOD, "Developing Novel Antimicrobial Agents Against Eye-Damaging Parasites," <u>Research to Prevent Blindness (RPB)</u> , 1-3 www.rpbusa.org .	
**57.	MIKLOSKA et al., "In vivo production of cytokines and beta (C-C) chemokines in human recurrent herpes simplex lesions--do herpes simplex virus-infected keratinocytes contribute to their production?" <u>J. Infect. Dis.</u> 177:827-838 (1997).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066778-0389	SERIAL NO. 10/549,482
	APPLICANT Daniel J. Carr et al.	
	FILING DATE September 16, 2005	GROUP 1644

**58.	MOORE et al., "The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy," <u>Invest. Ophthalmol. Vis. Sci.</u> 43:2905 (2002).	
**59.	NIEMIALTOWSKI and ROUSE, "Phenotypic and functional studies on ocular T cells during herpetic infections of the eye," <u>J. Immunol.</u> 148:1864 (1992).	
**60.	PAUSCH, "G-protein-coupled receptors in <i>Saccharomyces cerevisiae</i> : high-throughput screening assays for drug discovery," <u>Trends in Biotech.</u> 15:487-494 (1997).	
**61.	QIN et al., "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions," <u>J. Clin. Invest.</u> 101(4):746-754 (1998).	
**62.	RADER et al., "The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies," <u>J. Biol. Chem.</u> 275(18):13668-13676 (2000).	
**63.	RAJ, et al., "Corneal Graft Failure," <u>J. Bombay Ophthalmologists' Association</u> , 10(4):187-189 (2000).	
**64.	ROLLINS, "Chemokines," <u>Blood</u> 90:909 (1997).	
**65.	RUSSELL et al., "Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis," <u>Invest. Ophthalmol. Vis. Sci.</u> 25:938-944 (1984).	
**66.	SEO et al., "Murine keratocytes function as antigen-presenting cells," <u>Eur. J. Immunol.</u> 31:3318 (2001).	
**67.	SHIMELD et al., "Tracking the spread of a lacZ-tagged herpes simplex virus type 1 between the eye and the nervous system of the mouse: comparison of primary and recurrent infection," <u>J. Virol.</u> 75:5252 (2001).	
**68.	SMITH et al., "Anti-rat ICAM-1 antibody does not influence the course of experimental melanin-induced uveitis," <u>Curr. Eye Res.</u> 21(5):906-912 (2000).	
**69.	SOFIA, "Carbohydrate-based combinatorial libraries," <u>Mol. Divers.</u> 3:75-94 (1998).	
**70.	SPENCER et al., "Herpes simplex virus-mediated gene delivery to the rodent visual system," <u>Invest Ophthalmol. Vis. Sci.</u> 41:1392 (2000).	
**71.	STERRER et al., "Fluorescence correlation spectroscopy (FCS)--a highly sensitive method to analyze drug/target interactions," <u>J. Receptor and Signal Transduction Res.</u> 17:511-520 (1997).	
**72.	STREILEIN, et al., "Immunity causing blindness: five different paths to herpes stromal keratitis," <u>Immunology Today</u> , 18(9):443-449 (1997).	
**73.	SU et al., "Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection," <u>J. Virol.</u> 70:1277-1281 (1996).	
**74.	SUMMERS et al., "Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread," <u>J. Virol.</u> 75:5069-5075 (2001).	
**75.	SUZUKI et al., "Ocular surface inflammation induced by <i>Propionibacterium acnes</i> ," <u>Cornea</u> 21(8):812-817 (2002).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066778-0389	SERIAL NO. 10/549,482
	APPLICANT Daniel J. Carr et al.	
	FILING DATE September 16, 2005	GROUP 1644

**76.	TANG and HENDRICKS, "Interferon gamma regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas," <u>J. Exp. Med.</u> 184:1435 (1996).	
**77.	TANG et al., "Proinflammatory functions of IL-2 in herpes simplex virus corneal infection," <u>J. Immunol.</u> 158:1275-1283 (1997).	
**78.	TANIGAWA et al., "Natural killer cells prevent direct anterior-to-posterior spread of herpes simplex virus type 1 in the eye," <u>Invest. Ophthalmol. Vis. Sci.</u> 41:132 (2000).	
**79.	TATE et al., "Heterologous expression of G-protein-coupled receptors," <u>Trends in Biotech.</u> 14:426-430 (1996).	
**80.	THOMAS et al., "On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis," <u>J. Immunol.</u> 158:1383-1391 (1997).	
**81.	TIETZE et al., "Picking the needle from the haystack," <u>Curr. Biol.</u> 2:363-371 (1998).	
**82.	TUMPEY et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," <u>J. Leukoc. Biol.</u> 63:4486 (1998).	
**83.	TUMPEY et al., "Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea," <u>J. Virol.</u> 70:898-904 (1996).	
**84.	TUMPEY et al., "Absence of macrophage inflammatory protein-1alpha prevents the development of blinding herpes stromal keratitis," <u>J. Virol.</u> 72:3705-3710 (1998).	
**85.	WARD et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," <u>Nature</u> 341:544-546 (1989).	
**86.	WATKINS et al., "Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries," <u>Anal. Biochem.</u> 256(92):169-177 (1998).	
**87.	WINTER and HARRIS, "Humanized antibodies," <u>Immunol. Today</u> 14:243-246 (1993).	
**88.	WU et al., "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <u>J. Mol. Biol.</u> 294(1):151-162 (1999).	
**89.	ZAMORE, "RNA interference: listening to the sound of silence," <u>Nat. Struct. Biol.</u> 8:746-750 (2001).	

SDO 78141-1.066778.0389

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

** This reference not attached. Will be provided under separate cover.